Research Nester published a report titled “Liposome Drug Delivery Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of the global liposome drug delivery market in terms of market segmentation by product, technology, application, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, i.e., 2022 – 2031. The market is segmented by product into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Out of these, the liposomal doxorubicin segment is projected to garner the largest revenue of USD 3218.1 Million by the end of 2031. Additionally, in the year 2021, the segment generated a revenue of USD 1142.1 Million.
The global liposome drug delivery market is estimated to garner a revenue of USD 11977.1 Million by the end of 2031, up from a revenue of USD 4356.7 Million in the year 2021. Surge in need for advanced drug delivery systems, followed by the growing use of liposomes for drug delivery systems are some of the major factors anticipated to drive the growth of the market during the forecast period.
Geographically, the global liposome drug delivery market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in North America is projected to garner the largest revenue of USD 4429.6 Million by the end of 2031. Additionally, in the year 2021, the market in the region generated a revenue of USD 1689.9 Million.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Surge in the Prevalence of Cancer to Drive Market Growth
According to the statistics by the World Health Organization (WHO), one of the leading causes of death around the globe is cancer, which in the year 2020 registered close to 10 Million deaths.
The surge in prevalence of cancer around the globe is driving the need amongst the healthcare researchers to develop advanced drugs and drug delivery systems for the treatment of the disease. Liposomes, as a drug delivery system, have been known to be efficient for the treatment of cancer, which is anticipated to drive the growth of the market in the coming years.
However, the high cost of development of the drug delivery system is expected to operate as key restraint to the growth of global liposome drug delivery market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global liposome drug delivery market which includes company profiling of Spectrum Pharmaceuticals, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., Astellas Pharma Inc., Elan Pharmaceuticals (Perrigo Company plc), Merrimack Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., and others. Besides this, some of the prominent raw material manufacturers in the global liposome drug delivery market that are included in our report are NIPPON FINE CHEMICAL CO., LTD., Sonic Biochem Extractions Pvt. Ltd., Croda International Plc, Lipoid GmbH, Hashimoto Electronic Industry Co., LTD, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global liposome drug delivery market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.